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SUMMARY 
Exposure to progesterone is associated with increased risk of breast cancer in women. However, the 
role of progesterone receptor (PR) signaling on breast cancer development and progression is still 
largely unclear. In particular, the mechanistic basis of PR action on cancer cell movement and 
invasion have not been explored. In the present work, we characterized the rapid signaling events 
that follow the recruitment of PR in T47-D breast cancer cells that lead to morphological changes of 
cell shape and of the actin cytoskeleton which are implicated in the initiation of cell movement and 
invasion. In particular, we identified a set of extra-nuclear signaling events initiated by PR directed 
to the actin-regulatory protein, moesin. The PR-initiated activation of moesin is associated with a 
shift from globular to fibrillar actin and with a remodeling of the actin cytoskeleton toward the cell 
membrane in T47-D breast cancer cells. These processes lead to marked changes in the morphology 
of the cell membrane, particularly to the development of pseudopodia and ruffles, which are 
implicated in cell movement. Moesin is necessary for the cytoskeletal and cell membrane 
remodeling, as well as for T47-D cell horizontal movement and invasion of three-dimensional 
matrices initiated by PR. The signaling of PR to moesin requires the rapid extra-nuclear activation 
of the small GTPase RhoA and of its downstream effector Rho-associated kinase (ROCK-2), that is 
responsible for moesin phosphorylation. However, PR recruits RhoA via different signaling 
cascades depending on the ligand engaging its binding pocket. Indeed, in the presence of 
progesterone, progesterone receptor A (PRA) (but not PRB) is driven to interact with the G protein 
Gα13, leading to RhoA activation. However, in the presence of the synthetic progestin 
medroxyprogesterone acetate (MPA) both PRA and PRB interact with the tyrosine kinase c-Src 
which thus signals to phosphatidylinositol-3 kinase and then to RhoA. These results identify new 
mechanisms of action of PR in breast cancer cells that are linked to migration and invasion, and that 
may thus be important for breast cancer progression. This also identifies the actin cytoskeleton as an 
important target of regulation by PR in breast cancer cells. PR acts on these targets through an 
original, extra-nuclear set of signaling events converging on the actin-regulatory protein, moesin, 
that differ in part depending on the PR ligand. These results characterize new targets to potentially 
interfere with the PR-dependent promotion of breast cancer progression. 
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INTRODUCTION 
 
Sex steroids, including estrogens, progestins and androgens, play pivotal roles in the regulation of 
reproduction, development and metabolism. They are traditionally known to exert their actions 
through binding to steroid receptors (SRs) which are ligand-inducible transcription factors (1). 
Binding of steroid hormones to SRs induces a conformational modification of the receptor and 
allows homo/heterodimerization and nuclear translocation of the ligand-bound receptors and their 
binding to steroid response elements on the promoter regions of the target genes, thus regulating 
gene expression by interacting with the transcription machinery (1). 
 
However, a variety of cellular responses to steroid hormones are known which are characterized by 
a rapid time-lapse of activation as well as by their insensitivity to inhibitors of transcription (2). 
These actions have been collectively named as “nongenomic” to indicate the absence of a need for 
the receptor to translocate into the nucleus or “non-transcriptional” to highlight the fact that these 
actions are not exerted through regulation of gene expression. These actions are predominantly 
hypothesized to be elicited by membrane sex steroids receptors located on cell membrane. Indeed, a 
seminal step in the characterization of the non-nuclear actions of sex steroid receptors was made by 
Pietras and Szego in the late ‘70s by identifying the presence of binding sites for estrogen at the 
outer surface of endometrial cells and later by the purification in membrane fractions of functional 
estrogen receptors (3, 4). This finding first provided the evidence that these receptors could possibly 
do something different from the classical actions in the nucleus and gave a substantial background 
to the at the time unexplained observations of rapid actions of sex steroids. Since then, by using 
imaging techniques and overexpression systems, membrane localization of sex steroid receptors has 
been found in a variety of cell types, and has been shown to be play a role in the ability of these 
receptors to recruit nongenomic signaling pathways (2). Notwithstanding, the nature of these 
receptors located at the cell membrane has remained a conundrum for several years, and we still 
lack specific information on the events that determine cytoplasm or nuclear sex steroids receptors 
translocation to the plasma membrane respect to its shuttling between the cytoplasm and the nucleus.  
 
There has been growing evidence indicating that the nongenomic signaling mechanisms are 
implicated in multiple estrogen-regulated physiological and pathophysiological functions in 
different tissues (5). One of the best characterized non-genomic actions is represented by 
vasodilatation induced by sex steroids that occurs in a matter of seconds to minutes (6). This acute 
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effect is the result of a regulation of ion fluxes as well as of vasoactive molecules release on 
endothelial and VSMCs. A variety of nongenomi actions of sex steroids in the central nervous 
system have also been found  (7). Another potentially relevant action of the extra-nuclear signaling 
of sex steroids might be on breast cancer cells where sex steroids play important roles in breast 
cancer cell proliferation (8). 
 
In addition to these well-established nongenomic actions of sex steroids, recent evidence points out 
that sex steroids also regulate cell mobility via the regulation of rearrangement of cell actin 
cytoskeleton, which may be extremely important for the function of cell movement. We have 
recently described the presence of rapid actions of estrogens on the assembly of actin fibers in 
human endothelial cells. In particular, the exposure of these cells to physiological concentrations of 
estradiol leads to a rapid rearrangement of actin with a loss of stress fibers and the formation of 
cortical actin complexes. This actin remodeling parallels the formation of focal adhesion complexes 
and the development of endothelial cell membrane specialized structures, such as ruffles and 
pseudopodia, that are implicated in cell adhesion to the extracellular matrix, cell-cell interaction and 
cell movement. These phenomena depend on the rapid activation by phosphorylation of the actin-
regulatory protein moesin (9).  
 
Moesin, a member of the ezrin/radixin/moesin (ERM) family, is an actin-binding protein that plays 
an important role in cell motility by linking the actin cytoskeleton to a variety of membrane-
anchoring proteins (10, 11). In quiescent conditions moesin exists in an auto-inhibited conformation 
and phosphorylation of Thr558 within the C-terminal actin binding domain by the Rho-associated 
kinase (ROCK), results in a conformational change and in the association with the scaffold protein, 
ezrin/radixin/moesin-binding protein 50 (EBP50) on moesin’s NH2-terminal end and with F-actin 
on moesin’s COOH-terminal end to mediate the linkage of microfilaments to membranes in cell 
surface microvilli (12).  
 
Estrogen activates moesin in endothelial cells through a rapid, extra-nuclear signaling cascade 
originated by the interaction of ERα with the G protein Gα13. This process leads to the recruitment 
of RhoA and of the Rho associated kinase, ROCK-2 and to moesin activation. This pathway leads 
to the formation of membrane ruffles and pseudopodia which interact with the extracellular matrix 
and with nearby cells, thus promoting cell migration (9). 
 
Although this is a relatively recent area of investigation, it significantly expands our perception of 
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the scope of sex steroid nongenomic signaling and sheds new insight into their ability on the control 
of cell movement, which maybe critically relevant for a various of physiological or path-
physiological processes, such as injured vascular repair, wound healing, or cancer metastasis. 
 
Estrogen receptor status is tightly related to the progression and prognosis of breast cancer, and 
largely determines the efficiency of endocrine therapy. Indeed, the activation of estrogen receptor 
and the downstream nongenomic signalings mediates estrogen-induced migration and invasion of 
breast cancer cells (Simoncini T, et al., unpublished observations). However, the role of 
progesterone receptor (PR) signaling in the development and progression of breast cancer is poorly 
characterized notwithstanding its relevance in the clinical setting (13). To this extent, the 
Multiethnic Cohort and Women’s Health Initiative trials show an increased incidence of breast 
cancer in postmenopausal women receiving combined hormone therapy with estrogens and 
progestogens as compared to the women receiving estrogens alone, suggesting that progestins may 
play a deleterious role on breast cancer (14-16). 
 
The sex steroid progesterone and the various synthetic progestins act in human cells through 
progesterone receptor (PR) A and PRB (17). Beyond being transcription factors actively involved in 
the regulation of gene expression, PRs also act via rapid, extra-nuclear, signaling cascades, such as 
via the phosphatidylinositol 3-kinase (PI3K)/Akt or the c-Src/extracellular signal-regulated kinases 
1/2 (ERK1/2) pathways, playing an important role in breast cancer development (18, 19). However, 
little is known on the functional relevance of PR signaling for breast cancer progression. 
 
In this manuscript we investigate the regulatory actions of PR on breast cancer cell migration and 
invasion and we characterize the extra-nuclear signaling events recruited by PR. 
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MATERIALS AND METHODS 
Cell cultures and treatments 
T47-D breast cancer cells were incubated in RPMI 1640 medium containing 10% fetal calf serum 
(FCS), 0.2 UI/mL insulin, L-glutamine and penicillin streptomycin under a 5% CO2 atmosphere at 
37°C. Before experiments investigating non-transcriptional effects, cells were kept in DMEM 
containing no FBS for 8 hours. Whenever an inhibitor was used, the compound was added 30 
minutes before starting the treatments. Progesterone, medroxyprogesterone acetate, 17β-estradiol, 
hydrocortisone, pertussis toxin, Y-27632, PD98059, wortmannin, actinomycin D and cycloheximide 
were from Sigma-Aldrich (Saint-Louis, MO). 4-pregnen-3, 20-dione3-O-carboxymethyloxime: 
BSA (P-BSA) was from Steraloids (Steraloids incorporation, Newport, RI). 4-amino-5-(4-
chlorophenyl)-7-(t-butyl) pyrazolo (3,4-d) pyrimidine (PP2) was from Calbiochem (EMD 
Biosciences, Germany). ORG 31710 was a kind gift of Dr. Lenus Kloosterboer, from Organon Akzo 
Nobel (Oss, The Netherlands).  
 
Immunoblottings 
Cell lysates were separated by SDS-PAGE. Antibodies used were: moesin (clone 38, Transduction 
Laboratories, Lexington, KY), Thr558-P-moesin (sc-12895, Santa Cruz Biotechnology, Santa Cruz, 
CA), PR (sc-539, Santa Cruz), Tyr204-P-ERK (sc-7969, Santa Cruz), Gα13 protein (sc-410, Santa 
Cruz), ERK1/ERK2 (444944, Calbiochem-Novabiochem Corporation, San diego, CA), Thr34-P-Akt 
(07-789, Upstate, Lake Placid, NY), Akt (9272, Cell signalling technology, Danvers, MA). Primary 
and secondary Abs were incubated with the membranes with standard technique (52). 
Immunodetection was accomplished using enhanced chemiluminescence. Chemiluminescence was 
acquired with a quantitative digital imaging system (Quantity One, BioRad, Hercules, CA) allowing 
to check for saturation. Overall emitted photons were quantified for each band, particularly for 
loading controls, which were homogeneously loaded. 
 
Kinase assays 
T47-D cells were harvested in 20 mM Tris-HCl, 10 mM EDTA, 100 mM NaCl, 0.5% IGEPAL and 
0.1 mg/mL PMSF. Equal amounts of cell lysates were immunoprecipitated with Rhotekin RBD 
agarose (14-383, upstate) vs. GTP-RhoA or an Ab vs. ROCK-2 (C-20, Santa Cruz). The IPs were 
washed three times with buffer containing 20 mM Tris-HCl, 10 mM EDTA, 150 mM NaCl, 0.1% 
IGEPAL and 0.1 mg/mL PMSF. For ROCK-2 activity assay, two additional washes were performed 
in kinase assay buffer (20 mM MOPS, 25 mM β-glycerophosphate, 5 mM EGTA, 1 mM DTT) and 
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the samples were therefore resuspended in this buffer. 5 µg of de-phosphorylated myelin basic 
protein (Upstate) together with 500 µM ATP and 75 mM MgCl2 were added to each sample and the 
reaction was started at 30°C for 20 min. The reaction was stopped on ice and by resuspending the 
samples in Laemmli Buffer. The samples were separated with SDS-PAGE and Western analysis was 
performed using antibodies recognizing RhoA (sc-418, Santa Cruz) or Thr98-P-myelin basic protein 
(05-429, Upstate). 
 
Cell immunofluorescence 
T47-D breast cancer cells were grown on coverslips and exposed to treatments. Cells were fixed 
with 4% paraformaldehyde for 30 min and permeabilized with 0.1% Triton X for 5 min. Blocking 
was performed with 3% normal serum for 20 min. Cells were incubated with antibodies against 
Gα13 or PR (sc-418, Santa Cruz). After washing the nuclei were counterstained with 4'-6-diamidino-
2-phenylindole (DAPI) (Sigma) and actin was stained with Texas Red-phalloidin (Sigma). The 
coverslips were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, 
CA). Immunofluorescence was visualized using an Olympus BX41 microscope and recorded with a 
high-resolution DP70 Olympus digital camera. Pictures were photographed. Cell membrane 
thickness and the gray level of extracellular area, cell membrane as well as cytoplasm were 
quantitated using Leica QWin image analysis and image processing software (Leica Microsystems, 
Wetzlar, Germany). 
 
Transefection experiments 
On-TARGETplus SMARTpool siRNA reagents against human MAPK (NM-138957), ROCK-2 
(NM-004850), Src (NM-198291) and control siRNA (D-001810-01-05) were purchased from 
Dharmacon (Thermo Fisher Scientific Inc, USA). T47-D cells were transfected with siRNA using 
Lipofectamine (Invitrogen) according to the protocol. Cells (40% confluent) were serum-starved for 
1 h followed by incubation with 100 nM target siRNA or control siRNA for 6 h in serum-free media. 
The serum-containing media was then added (10% serum final concentration) for 42 h before 
experiments and/or functional assays were conducted. Target protein silencing was assessed through 
protein analysis up to 48 h after transfection. 
 
Each plasmid (15 µg) was transfected into T47-D breast cancer cells using the Lipofectamine 
(Invitrogen) according to the manufacturer’s instructions. The transfected plasmids were as follows: 
Gα13 Q226L, Gα13 Q226L/D294N, RhoA T19 and RhoA G14V, p85α or dominant-negative p85α (∆ 
p85α). These constructs were obtained from the Guthrie cDNA Resource Center (www.cdna.org). 
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Plasmids for CMV human progesterone receptor A (hPR-A, # 95) and B (hPR-A, # 90) were 
provided by Dean P. Edwards (Baylor college of medicine, USA).  All the inserts were cloned in 
pcDNA3.1+. As control, parallel cells were transfected with empty pcDNA3.1+ plasmid. Cells (60-
70% confluent) were treated 24 h after transfection, and cellular extracts were prepared according to 
the experiments to be performed. 
 
Validated antisense phosphorotioate oligonucleotides (S-modified) (PONs) complementary to the 
1–15 position of the human moesin gene coding region were obtained from Dharmacon. The 
sequence was 5'-TACGGGTTTTGCTAG-3' for moesin antisense PON. The complementary sense 
PON was used as control (5'-CTAGCAAAACCCGTA-3'). Transfections were performed on 
subconfluent T47-D cells. PONs were resuspended in serum-free medium with Lipofectamine 
(Invitrogen) and added to the culture medium every 12 h at the final concentration of 4 µM. Every 
24 h, cells were washed and fresh medium supplemented with 4 µM PONs was added. Moesin 
silencing was assessed through protein analysis up to 48 h after transfection. 
 
G-actin /F-actin in vivo assay 
G-actin/F-actin in vivo assay kit was purchased from Cytoskeleton Inc (# BK037, Denver, USA). 
This kit is used to determine accurately the amount of filamentous actin (F-actin) content versus 
free globular-actin (G-actin) content in a cell population. In brief, confluent T47-D cells were 
harvested with 37°C warm lysis and F-actin stabilization buffer (50 mM PIPES, 50 mM KCl, 5 mM 
MgCl2, 5 mM EGTA, 5% glycerol, 0.1% Nonidet P40, 0.1% Triton X-100, 0.1% Tween 20, 0.1% 2-
mercapto-ethanol, 0.001% antifoam C, 1 mM ATP) after required treatments. Total protein 
concentration was determined by standard method. Positive and negative controls were set by 
adding F-actin enhancing solution (phalloidin, 1 µM) or F-actin depolymerization solution (10 µM 
cytochalasin-D) to the lysates, respectively. The lysates were incubated at 37°C for 10 min, 
followed by a centrifuge at 2000 rpm for 5 min to pellet and discard unbroken cells. Supernatant 
were centrifuged at 10,000 × g for 1 h at 37°C. After that, supernatant and pellet were both collected. 
Pellets were resuspended to the same volume as the supernatant using ice cold distilled water plus 
F-actin depolymerization solution (10 µM cytochalasin-D) and put on ice for 1 h to dissociate F-
actin. According to the protein concentration previously measured, equivalent volumes of 
supernatant and dissolved pellet were loaded to run Western blot and G-actin/F-actin ratio was 
quantitiated using the quantitative digital imaging system. 
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Cell migration assays 
Cell migration was assayed with razor scrape assays as previously described (9). Briefly, a razor 
blade was pressed through the confluent T47-D breast cancer cell monolayer into the plastic plate to 
mark the starting line. T47-D cells were swept away on one side of that line. Cells were washed, 
and 2.0 mL of DMEM containing steroid-deprived FBS and gelatin (1 mg/mL) were added. 
Cytosine β-D-arabinofuranoside hydrochloride (Sigma) (10 µM), a selective inhibitor of DNA 
synthesis which doesn’t inhibit RNA synthesis was used 1 h before the test substance was added. 
Migration was monitored for 48 hours. Every 12 h fresh medium and treatment were replaced. Cells 
were digitally imaged and migration distance was measured by using phase-contrast microscopy.  
 
Cell invasion assays 
Cell invasion were assayed following the standard method by using the BD BioCoatTM Growth 
Factor Reduced (GFR) MatrigelTM Invasion Chamber (BD Bioscience, USA). In brief, after 
rehydrating the GFR Matrigel inserts, the test substance was added to the wells. An equal number of 
Control Inserts (no GFR Matrigel coating) were prepared as control. 0.5 mL of T47-D cell 
suspension (2.5 × 104 cells/mL) were added to the inside of the inserts. The chambers were 
incubated for 24 h at 37°C, 5% CO2 atmosphere. After incubation, the non-invading cells were 
removed from the upper surface of the membrane using cotton tipped swabs. Then the cells on the 
lower surface of the membrane were stained with Diff-Quick stain. The invading cells were 
observed and photographed under the microscope at 100 × magnification. Cells were counted in the 
central field of triplicate membranes. The invasion index was calculated as the % invasion test cell/ 
% invasion control cell. 
 
Statistical analysis 
All values are expressed as mean ± SD. Statistical differences between mean values were 
determined by ANOVA, followed by the Fisher’s protected least significance difference (PLSD). All 
differences were considered significant at P < 0.05. 
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RESULTS 
 
Rapid activation of PR is linked to breast cancer cell cytoskeletal and cell membrane 
rearrangement 
Actin fibers in ER+/PR+ T47-D breast cancer at baseline were arranged longitudinally in the 
cytoplasm and the cell membrane was regular. Activation of PR with either natural progesterone (P, 
100 nM) or the synthetic progestin medroxyprogesterone acetate (MPA, 100 nM) resulted in a rapid 
shift of the actin fibers toward the edge of the membrane. This was associated with a significant 
increase of the thickness of the cell membrane and of its fluorescence intensity, quantified by 
analyzing the pixel intensity in a box including the cell membrane as well as the adjacent intra- and 
extra-cellular space (Fig. 1A, 1B and Table. 1). In parallel, cell membrane ruffles and pseudopodia 
were formed at sites enriched in actin (Fig. 1A). These effects were maximal between 10 and 15 
minutes and began to revert after 30 minutes (Fig. 1A, 1B and Table. 1). These processes were 
prevented by the pure PR antagonist ORG 31710 (Fig. 1A, 1B and Table. 1). 
 
When the globular/fibrillar (G/F) actin ratio was assayed in T47-D cells, similar changes were 
observed. At baseline, actin predominantly existed as monomers (G-actin), while after recruitment 
of PR with P or MPA for 15 min, a rapid shift toward F-actin was found that was prevented by ORG 
31710 (Figure 1C), indicating that PR activation is linked to rapid actin polymerization. The amount 
of total actin (G-actin + F-actin) was comparable in all conditions (Figure 1C). 
 
Recruitment of PR leads to activation of the actin-regulatory protein, moesin
In analogy with what is known for ERα (9) we tested if PR controls actin organization via the actin-
binding protein, moesin. Thr558-phosphorylation (which corresponds to activation) (12) of moesin 
rapidly increased in T47-D cells exposed to P (100 nM) or MPA (100 nM) between 2 (mean 
increases of moesin phosphorylation: P 73%, MPA 102%) and 15 minutes (mean increases of 
moesin phosphorylation: P 183%, MPA 268%) and then declined after 30 minutes, time-consistently 
with the kinetics of actin rearrangement (Fig. 2A-B). Moesin activation was related to concentration 
of the PR agonists (Fig. 2C-D). Supporting the requirement of PR, the same PR agonists did not 
alter moesin phosphorylation in MDA-MB-468 breast cancer cells, that do not express PR (Fig. 2E-
F).  
 
To establish the requirement of moesin for the PR-induced actin reorganization in T47-D cells we 
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silenced moesin expression by transfecting specific antisense phosphorotioate oligonucleotides 
(PONs). After exposure to antisense moesin PONs for 48 h, moesin protein expression (Fig. 2G) 
and cell immunostaining (Fig. 2H) in T47-D cells were greatly reduced. Moesin-silenced T47-D 
cells did not respond with actin or cell membrane remodeling when PR was recruited by either P or 
MPA (Fig. 2H). As control, non-transfected T47-D cells or cells receiving sense (inactive) moesin 
PONs displayed a visible cytoskeletal and cell membrane reorganization in response to PR 
recruitment (Fig. 2H).  
 
Characterization if the initiation of PR signaling to moesin 
The rapid time lapse of moesin activation and deactivation suggests that PR signals to this protein 
via “nongenomic” or “extra-nuclear” cascades (20). Indeed, activation of PR with either P or MPA 
still resulted in moesin activation even if RNA or protein synthesis was blocked in T47-D cells with 
actinomycin D (Act D - 10 µM) or cycloheximide (CHX - 200 µM) (Fig. 3A).  
 
Blockade of PR with ORG 31710 completely abolished both progesterone and MPA-dependent 
moesin activation, confirming that PR is the steroid receptor used by these agonists to signal to 
moesin (Fig. 3B-C). Interference with the ERK1/2 cascade with PD98059 did not alter the 
activation of moesin (Fig. 3B-C). Interestingly, inhibition of G proteins with pertussis toxin (PTX) 
prevented the activation of moesin by P but not by MPA, while inhibition of phosphatidylinositol-
3OH kinase (PI3K) with wortmannin exclusively blocked the action of MPA but not that of P (Fig. 
3B-C). These findings indicate that PR signals to moesin via a G protein-dependent pathway when 
bound by P, and via a PI3K-dependent pathway in the presence of MPA.  
 
PR ligands exert their actions through the two PR isoforms, PRA and PRB, which are both 
expressed by the T47-D cells used in this study (Fig. 3D). However, in contrast to P, MPA also 
binds the glucocorticoid receptor (GR), that mediates some of its actions (21, 22). This different 
receptor binding pattern explains some of the biological differences of the two compounds (21, 22). 
However, phosphorylation of moesin in the presence of MPA was equally prevented by the pure PR 
antagonist ORG 31710 as well as by the mixed PR/GR antagonist RU486, suggesting that GR does 
not play a role in MPA signaling to moesin (Fig. 3E). In agreement, moesin was not phosphorylated 
in the presence of hydrocortisone (50 nM) (Fig. 3E). 
 
PR activation of ERK1/2 and PI3K in breast cancer cells is associated with cell proliferation and 
inhibition of apoptosis (18, 23). Consistent with these reports, exposure of T47-D cells to P resulted 
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in a time-dependent activation of ERK1/2 and of the PI3K effector, Akt (Fig. 4A-B).  
 
However, recruitment of PR with either P or MPA in T47-D cells after silencing of ERK 1/2 with 
siRNAs (Fig. 4C) still resulted in activation of moesin (Fig. 4D), confirming that signaling of PR to 
the ERK1/2 mitogen-activated protein kinase (MAPK) cascade is not implicated in moesin 
activation. 
 
Transfection of T47-D cells with a dominant negative form of the regulatory subunit of PI3K, p85α 
(∆p85α), resulted in the impairment of the PR-dependent moesin activation induced by MPA, but 
had no inhibitory effect on P (Fig. 4E), implying that PI3K only plays a role in PR signaling to 
moesin induced by MPA. As control, the transfection of a wild-type p85α construct (WT p85) did 
not alter moesin activation induced by P nor MPA (Fig. 4E). 
 
The G protein Gα13 is an established controller of the cytoskeleton and of cell movement (24). Gα13 
mediates estrogen-induced actin remodeling and cell migration in endothelial cells (9). We thus 
checked if Gα13 is recruited by PRs. 
 
Co-immunoprecipitation studies showed that, in the presence of progesterone, PRA started to 
interact with Gα13. The PRA/Gα13 interaction was ligand-dependent, being prevented by ORG 
31710, but not by PTX (Fig 5A). In addition, the PRA/Gα13 interaction was ligand-specific, as it 
was not triggered by MPA (Fig. 5A). Differently from PRA, a basal interaction between PRB and 
Gα13 was found, which was not altered by the addition of either P or MPA (Fig. 5A). 
 
As G proteins reside on the cell-membrane and sub-sets of PRs have also been identified at this 
level (25, 26), we used the membrane-impermeable bovine serum albumin-progesterone conjugate 
(P-BSA - 100 nM) to explore if binding of PR at the cell membrane may be involved in moesin 
activation. Indeed, exposure of T47-D cells to P-BSA resulted in rapid activation of moesin (Fig. 
5B). 
 
PR interacts with the tyrosine kinase c-Src (27), and this process is involved in the activation of 
PI3K (28). We thus explored the role of c-Src for the PR-dependent activation of moesin induced by 
MPA. Administration of MPA to T47-D cells lead to activation of the PI3K target Akt and of moesin, 
both  of which were prevented by the Src kinase inhibitor, PP2 (Fig. 5C-D). Activation of Akt and 
moesin were associated with a ligand-induced interaction of both PRA and PRB with c-Src (Fig. 
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5E-F). 
 
Silencing of c-Src with specific siRNAs (Fig. 5G) impaired the activation of moesin by MPA (Fig 
5H). In contrast, P was still able to trigger moesin phosphorylation in c-Src-silenced cells (Fig. 5H), 
reinforcing the hypothesis that PR signaling to moesin is ligand-specific, and that the interaction 
with c-Src and the subsequent recruitment of the PI3K/Akt pathway are absolutely required when 
PR is engaged by MPA, but not in the presence of P. 
 
To further differentiate the role of the two PR isoforms, we transfected full-length human PRA or 
PRB in ER-/PR- MDA-MB-231 breast cancer cells and studied the interaction with Gα13 or c-Src 
and the activation of moesin. 
 
In MDA-MB-231 cells transfected with the vector plasmid pcDNA3.1+, baseline or ligand-
associated interaction of PR with Gα13 or c-Src was negligible and no moesin activation was 
observed (Fig. 5I). In MDA-MB-231 cells transfected with PRA, P (but not MPA) enhanced the 
interaction of PRA with Gα13 (Fig. 5I). In the same cells enhanced interaction of PRA with c-Src 
was found in the presence of both P and MPA (Fig. 5I). In this experimental condition, exposure to 
P as well as to MPA was associated with increased moesin phosphorylation (Fig. 5I).
 
When MDA-MB-231 cells were transfected with PRB, a visible co-interaction of this receptor with 
Gα13 was seen, which was not altered by the presence of the ligands (Fig. 5I). Interaction of PRB 
with c-Src was instead dependent on the presence of either P or MPA (Fig. 5I). However, in these 
cells, only exposure to MPA resulted in activation of moesin. 
 
Overall, these results indicate that PRA is responsible for the recruitment of Gα13, but this 
interaction requires the presence of P, while it does not ensue with MPA. While PRB interacts with 
Gα13, this does not seem to be important for the signaling to moesin, as this interaction is not 
modulated by ligands. In parallel, interaction with c-Src is supported for both PRA and PRB by 
either P or MPA, but it mediates only the signaling of MPA to moesin, not that of P. Thus, signaling 
to moesin in T47-D cells is initiated through a PRA/Gα13 interaction in the presence of progesterone, 
or alternatively through a PRA/B-dependent recruitment of c-Src when MPA is present. 
 
Later intracellular events linking activation of PR to moesin: role of RhoA 
The small GTPase RhoA mediates the signaling of a variety of receptors to ERM proteins, including 
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that of sex steroid receptors (9). Indeed, PR activation in T47-D cells with P or MPA increased the 
amount of active, GTP-bound RhoA (Fig. 6A-B). In agreement with the previous results, the PR-
dependent recruitment of RhoA was mediated by G proteins in the presence of P (Fig. 6A), while it 
involved PI3K, and not G proteins, in the presence of MPA (Fig. 6B). 
 
Supporting the role of Gα13 and RhoA in the signaling of PR, moesin phosphorylation was ligand-
independently induced by transient transfection of Gα13 (Gα13 Q226L) or RhoA (RhoA G14V) 
constitutively active constructs (Fig. 6C-D). In parallel, transfection of a dominant negative RhoA 
(RhoA T19N) construct resulted in a significant reduction of P- and MPA-induced moesin 
phosphorylation (Fig. 6C-D). In line with the previous results, a dominant negative Gα13 construct 
(Gα13 Q226L/D294N) decreased the amount of moesin phosphorylation induced by P but not by 
MPA (Fig. 6C-D). 
 
Later intracellular events linking activation of PR to moesin: role of the Rho-associated kinase, 
ROCK-2 
Phosphorylation of moesin by the Rho-associated kinase (ROCK-2) is crucial for the formation of 
microvilli and other specialized cell membrane structures (12). Blockade of ROCK-2 with the 
specific inhibitor Y-27632 prevented the PR-dependent moesin activation induced by P or MPA (Fig. 
7A-B). In addition, silencing of ROCK-2 with siRNAs (Fig. 7C) prevented the PR-dependent 
moesin activation induced by both P and MPA (Fig. 7D). 
 
In the presence of progesterone, ROCK-2 was functionally activated, as shown by enhanced Thr-
phosphorylation of the bait protein myelin basic protein (MBP) by ROCK-2 immunoprecipitates 
(IPs) (Fig. 7E). ROCK-2 activation by P was prevented by the PR antagonist ORG 31710 and by 
the G protein inhibitor, PTX (Fig. 7E). Recruitment of PR by MPA also lead to ROCK-2 activation 
(Fig. 7F). ORG 31710 and the PI3K inhibitor wortmannin inhibited this action of MPA, while PTX 
was ineffective (Fig. 7F).   
 
Signaling of PR to ROCK-2 and moesin drives breast cancer cell migration and invasion 
Activation of PR with P or MPA in T47-D breast cancer cells pre-treated with cytosine β -D-
arabinofuranoside hydrochloride (Ara-C - 10 µM) to prevent cell division resulted in enhanced 
migration vs. vehicle-treated cells (Fig. 8A-B). This was inhibited by blocking PR or ROCK (Fig. 
8A-B). Silencing of moesin with antisense oligonucleotides (PON) fully prevented the effect of P 
and MPA, as well (Fig. 8A-B). Inhibition of G proteins resulted in a near-complete blockade of cell 
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migration in the presence of either P or MPA (Fig. 8A-B), consistent with a broader role of G 
proteins for cell movement, that likely overrides the PR-to-ROCK cascade. Inhibition of PI3K or of 
MAPK decreased both P- and MPA-promoted cell migration to some extent (Fig. 8A-B). However, 
a statistically significant reduction of cell migration was found only for the addition of PD98059 to 
P treatment (Fig. 8A) and for the addition of wortmannin to MPA treatment (Fig. 8B).  
 
To address the question whether PR signaling to moesin may be important for cell invasion, we 
used Ara-C-pre-treated T47-D cells in three-dimensional matrigel invasion assays. In this setting, 
recruitment of PR with P or MPA promoted invasion of the matrix by cancer cells (Fig. 9A-B). The 
number of cells that invaded the matrix in the presence of MPA was higher than with P (Fig. 9A-B). 
The invasive behavior induced by P or MPA was prevented by blocking PR, G proteins or ROCK-2 
(Fig. 9A-B). Inhibition of moesin expression by transfection of antisense oligonucleotides (PON) 
reduced cell invasion induced by PR in the presence of both ligands (Fig. 9C). Lesser inhibitory 
effects were found in when the MAPK inhibitor, PD98059 and of the PI3K inhibitor, wortmannin 
were added to either P or MPA (Fig. 9A-B). 
 
PR activation induces changes of cell morphology and promotes cell movement in live cells 
Finally, we studied cell morphology with time-lapse microscopy during PR activation in T47-D 
cells. In the absence of PR ligands, T47-D breast cancer cells are nearly static, without obvious 
morphologic changes throughout a 30 min time lapse at 37°C (Fig. 10A). In contrast, an rapid 
change of cell morphology is seen with the addition of progesterone or MPA, starting as early as 2 
min from the addition of the compounds to the cell culture medium (Fig. 10B-C). As P or MPA 
were added on one corner of the cell culture dish, without mixing the medium, the formation of a 
directional gradient of concentration of the compounds is expected. To this extent, throughout the 
30 min time lapse, a slight directional movement of the observed cells towards the area of the dish 
where the drug was added could be seen (Fig. 10B-C).   
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DISCUSSION 
Progesterone receptor is a fundamental orchestrator of breast development and function (29), but is 
also implicated in breast cancer development and progression, although its role in these processes is 
still to be fully established (13). Nonetheless, recent evidence from clinical trials (15, 30, 31) 
suggests that exposure to progesterone may a key factor for breast cancer. 
 
Cancer cells spread locally and metastasize to distant organs and these processes represent the chief 
cause of morbidity and death (32). Endocrine therapy using the progesterone receptor (PR) 
antagonist RU486 prevents the development of mammary tumors and induces the regression of 
lymph node and lung metastases in mouse breast cancer models (33, 34), supporting a role for PR in 
these processes. In addition, PR agonists enhance the invasiveness of breast cancer cells by 
increasing tissue factor or vascular endothelial growth factor expression (35, 36). However, 
definitive mechanistic explanations of the effects of PR on breast cancer cell movement or invasion 
are not available. 
 
Cell movement is a complex and highly integrated process. The formation of a cortical actin 
complex at specialized membrane structures, such as pseudopodia, lamellipodia and membrane 
ruffles (37) bridges the cytoskeleton to the extracellular matrix. The actin-binding protein moesin 
plays a central role in these processes (37, 38). 
 
Our previous findings show indicate that sex steroid receptors, such as the estrogen receptor alpha, 
control moesin activity in vascular cells (9). In this paper, we discover that PR signals to moesin in 
breast cancer cells and this leads to rapid actin remodeling that supports horizontal cell movement 
and invasion of three-dimensional matrices. Moesin is required for these tasks, as its silencing 
results in reduced migration in the presence of progestins. These findings are consistent with 
previous reports of effects of progesterone on the formation of adhesion structures and on 
cytoskeletal modifications in other breast cancer cell lines (39). 
 
In the presence of progesterone, PRA interacts with the G protein Gα13, therefore recruiting the 
RhoA/ROCK-2 cascade. This results in moesin phosphorylation and in the morphological changes 
in the cell. PRB also interacts with Gα13, however, this interaction is not dependent on the presence 
of a ligand, nor it recruits the Gα13/RhoA/ROCK-2 cascade. 
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The finding of the interaction of PRA and Gα13 is consistent with previous reports of PR signaling 
through Gαi and Gβγ (25, 40, 41). Gα13 belongs to the G12 family that is critical for cell movement 
and plays an important role in metastasis (24, 42). Indeed, expression of activated Gα13 in breast 
cancer cells increases cell invasion (43). Our finding of the recruitment of Gα13 by PRA thus 
provides a mechanistic explanation for the progesterone-dependent breast cancer cell migration and 
invasion.  
 
Recent work indicates the existence of membrane-localized progesterone receptors (25, 26). As 
Gα13 is a cell membrane protein, the finding that moesin phosphorylation can be induced by a 
membrane-impermeable form of progesterone might be compatible with the recruitment of PRA at 
this level. However, this is just suggestive and not conclusive. The identification of the cellular site 
of PR/Gα13 interaction is therefore not solved and will be the aim of future studies. 
 
In normal mammary epithelial cells PR isoforms are co-expressed equivalently. However, PR 
isoform predominance, especially PRA predominance or an increased PRA/PRB ratio, is found in a 
high proportion of breast cancers and correlates to invasive behaviour (44, 45). Moreover, an 
increased PRA/PRB ratio in breast cancer cells has been shown to induce changes in cell 
morphology and the loss of cell adhesion in response to progesterone receptor agonists, along with a 
membrane-to-cytoplasm redistribution of the ERM protein, ezrin (46). Increasing PRA levels in 
breast cancer cells is also associated with altered expression of genes associated with regulation of 
cell shape and adhesion (47). More recently PRB (but not PRA) has been shown to localize to the 
cytoplasm in response to progesterone and thus to interact with c-Src. This leads to the activation of 
MAPK and to subsequent up-regulation of cyclin D1 in breast cancer cells (19). To this extent, our 
finding of a divergent ability of PRA and PRB to recruit the RhoA/ROCK-2 cascade stands in 
favour of a different role of the two receptor isoforms during cell migration and invasion. 
 
PR-dependent recruitment of the MAPK and PI3K/Akt pathways in the presence of natural 
progesterone does not seem to be involved in moesin activation, but the inhibition of these two 
pathways decreases cell migration and invasion in T47-D cells exposed to progesterone. This 
implies that moesin is not the exclusive tool mediating cell migration and invasion in the presence 
of this PR agonist, which is not surprising. On the other hand, PRA does not interact with Gα13 
when bound by the synthetic progestin, MPA, indicating a high degree of specificity of this 
signaling event. Indeed, when MPA hits PRA or PRB, the Src/PI3K/Akt pathway is rapidly 
recruited. This ultimately leads to the activation of RhoA and ROCK-2 and, finally, of moesin. It is 
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possible that when engaged by MPA, PRs may be driven to form a functional signaling module 
with Src and PI3K, where activated PI3K would lead to recruitment of RhoA, as shown in other 
cells (48). In analogy, ER, Src and PI3K are reportedly organized into a similar complex to mediate 
rapid signaling of estrogens in endothelial cells (49). 
 
While PI3K is critical for moesin activation by MPA, G proteins and MAPK are still relevant for 
MPA-induced cell migration. A similar result is found for breast cancer invasion of three-
dimensional matrices, where the inhibition of G proteins, ROCK and MAPK all result in a 
significant decrease of progesterone-induced cell invasion, notwithstanding the fact that MAPK are 
not required for moesin activation by progesterone. These apparent discrepancies are likely due to 
the complexity of the processes of cell movement and invasion, that are controlled by multiple 
internal and external signals (50). 
 
Some of the present results point out that PR signals differently when engaged by different agonists, 
such as P or MPA. The basis for this phenomenon are not currently understood. Progestins act 
differentially in part due to the ability to engage other steroid receptors (51). MPA is able to bind 
the glucocorticoid receptor (GR) and this explains some effects of this progestin in endothelial cells 
(21). However, GR is not responsible for the MPA-dependent activation of moesin, possibly 
indicating that conformational differences in PR might explain the differential recruitment of 
signaling pathways in the presence of the two ligands. 
 
In conclusion, we show that PR is implicated in breast cancer cell migration and invasion. 
Recruitment of PR by P or MPA leads to rapid extra-nuclear signaling to actin, associated to the 
rearrangement of the cytoskeleton and the formation of pseudopodia and membrane ruffles. These 
changes increase breast cancer cell invasion of the surrounding environment. PR signaling seems to 
be ligand-specific, as in the presence of progesterone PR signals to RhoA and ROCK-2 through the 
activation of Gα13, while in the presence of MPA PR uses c-Src and PI3K. These observations help 
to understand the role of progesterone receptor signaling in breast cancer spread and could provide 
new molecular targets for breast cancer treatment.
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Table Legend 
 
Table. 1. The table displays the mean thickness of the cell membrane, the mean actin 
intensity of the membrane and the cytoplasm, as well as the ratio of the intensities of 
membrane/cytoplasm in T47-D cells treated with progesterone and MPA (both 100 nM) for 
different times, in the presence or absence of PR antagonist ORG 31710 (1 µM). Analytic 
results were obtained by using Leica QWin image analysis and processing software. 
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Figure Legends 
 
Fig. 1. PR activation induces a rapid rearrangement of the actin cytoskeleton in T47-D 
cells. (A) T47-D cells were treated with P or MPA (both 100 nM) for 10, 15 or 30 minutes, in 
the presence or absence of the pure PR antagonist ORG 31710 (1 µM). Immunofluorescent 
analysis of Texas Red-phalloidin (in red) reveals the spatial modifications of actin fibres 
through the time-course and the formation of specialized cell membrane structures. Green, 
yellow and light blue arrows indicate lamellipodia, pseudopodia and ruffles, respectively. 
Nuclei are counterstained in blue. Rectangles indicate the area sampled in the corresponding 
upper graph. In the graph, the longitudinal axis displays the gray level and the horizontal axis 
shows the pixels. Light yellow, light red and light blue areas indicate the parts of the graph 
indicating the extracellular, plasma membrane and cytoplasmic areas. (B) Analytic results 
obtained by using Leica QWin image analysis and processing software showing the mean 
thickness of the cell membrane after treatment with P or MPA (both 100 nM). The results are 
derived from the sampling of five areas of the cell membrane of thirty different random cells. 
The areas of minimum and maximum cell membrane thickness were always included. The 
results are the mean ± SD of the measurements. (C) shows the amount of filamentous actin 
(F-actin, F) versus free globular-actin (G-actin, G) content in T47-D cells after treatment with 
P or MPA (both 100 nM) for 15 min, in the presence or absence of PR antagonist ORG 31710 
(1 µM). Positive (Pos) and negative (Neg) controls were set by adding F-actin enhancing 
solution (phalloidin, 1 µM) or F-actin depolymerization solution (10 µM cytochalasin-D) to 
the lysates, respectively. 
 
Fig. 2. PR activation turns into moesin activation. (A), (B) (C) and (D) show the time- and 
dose-dependent moesin activation in T47-D breast cancer cells after recruitment of PR with P 
or MPA. Total cell amount of wild-type (Moesin) or Thr558-phosphorylated moesin (P-Moesin) 
are shown with western blot. (E) and (F) show that in MDA-MB-231 cells (that do not 
express PR), progesterone and MPA have no effect on moesin activation. (G) Moesin 
expression detected by western blot in T47-D cells transfected with moesin antisense PON 
for 48 h. (H) Actin remodeling after PR activation with P or MPA for 15 min in T47-D cells 
after transfection with moesin antisense phosphorotioate oligonucleotides (PON) (antisense - 
2 µM) or sense PON (sense - 2 µM) for 48 h. Cells were stained with an Ab vs. moesin (FITC; 
green staining) as well as with Texas Red-phalloidin (in red). Nuclei are counterstained in 
blue.  
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Fig. 3. Extra-nuclear signaling of PR to moesin in T47-D cells. (A) T47-D cells were 
treated with progesterone or MPA (both 100 nM) for 15 min, in the presence or absence of 
Act D (10 µM) or CHX (200 µM). Moesin and phosphorylated moesin are shown. (B) and (C) 
Cells were exposed to 100 nM progesterone or MPA for 15 min, in the presence or absence of 
the pure PR antagonist ORG 31710 (ORG - 1 µM), of the MEK inhibitor PD98059 (PD - 5 
µM), of the PI3K inhibitor wortmannin (WM - 30 nM) or of the G protein inhibitor, PTX 
(100 ng/mL). Cell contents of wild-type or phosphorylated moesin are shown. (D) The 
expression of PRA and PRB in T47-D cell lysates is shown (M - marker proteins). (E) Cells 
were exposed to 100 nM MPA or 50 nM hydrocortisone (Hydr) for 15 min, in the presence or 
absence of ORG 31710 (ORG - 1 µM) or of the combined GR/PR antagonist, RU486 (RU - 1 
µM), moesin and phosphorylated moesin are assayed with western analysis. 
 
Fig. 4. Extra-nuclear signaling of PR to moesin in T47-D cells: ERK1/2 and PI3K. (A) 
shows wild-type (ERK1/ERK2) or phosphorylated ERK 1/2 (P-ERK1/ERK2) during 
exposure to progesterone (100 nM). (B) Shows wild-type (Akt) and phosphorylated Akt (P-
Akt) in the presence of 100 nM P. (C) T47-D cells were transfected with scrambled siRNA or 
ERK1/2 targeted siRNAs for 48 h. After that level of ERK1/2 protein expression was 
detected by western blot as indicated. (D) Cells were exposed to 100 nM P or MPA for 15 
min after transfection with 100 nM targeted siRNA for ERK1/2 or scrambled siRNA for 48 h. 
Cell contents of wild-type or phosphorylated moesin are shown. (E) Cells were exposed to 
100 nM progesterone or MPA for 15 min after transfection with constitutively active p85α 
(WT p85α) or dominant-negative p85α (∆p85α) for 48 h. Cell contents of p85α, wild-type or 
phosphorylated moesin are shown. 
 
Fig. 5.  Extra-nuclear signaling of PR to moesin in T47-D cells: Gα13 and c-Src. (A) T47-
D cells were treated for 15 minutes with P or MPA (both 100 nM), in the presence or absence 
of ORG 31710 (ORG - 1µM) or of PTX (100 ng/mL). Protein extracts were 
immunoprecipitated with an Ab vs. Gα13 and the IPs were assayed for co-
immunoprecipitation of PRs. The cell extract (30 µg) was used as input and normal rabbit 
IgG was used as the control antibody. (B) T47-D cells were exposed to 100 nM P-BSA 
(membrane-impermeable) for 15 min, in the presence or absence of ORG 31710 (ORG - 1 
µM). Moesin and phosphorylated moesin are shown. (C) and (D) T47-D cells were treated 
with 100 nM MPA for 15 min, with or without the Src kinase inhibitor, PP2 (10 µM) and 
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wild-type or active Akt or moesin are shown. (E) and (F) T47-D cells were treated for 15 
minutes with 100 nM MPA, in the presence or absence of ORG 31710 (ORG - 1 µM). Protein 
extracts were immunoprecipitated with an Ab vs. PR (E) or c-Src (F) and the IPs were 
assayed for co-immunoprecipitation of PR or c-Src as indicated. Cell extract (30 µg) was 
used as input. Normal rabbit IgG and normal mouse IgG were used as the control antibodies 
in (E) and (F), respectively. (G) T47-D cells were transfected with scrambled siRNA or c-Src 
targeted siRNAs for 48 h. c-Src protein expression was detected by western blot as indicated. 
(H) T47-D cells were exposed to 100 nM P or MPA for 15 min after transfection with c-Src 
siRNA or non-specific control siRNAs for 48 h.  Total moesin or P-moesin cell amounts are 
shown. (I) PR-negative MDA-MB-231 cells were transiently transfected with empty 
pcDNA3.1+ plasmid (vector) or plasmids encoding full length of human PRA or PRB for 48 
h, then cells were exposed to 100 nM P or MPA for 15 min. Protein extracts were 
immunoprecipitated with an Ab vs. PR, and the IPs were assayed for co-immunoprecipitation 
of Gα13 or c-Src as indicated. Total moesin and phosphorylated moesin were also analyzed 
using western blot. 
 
Fig. 6. Extra-nuclear signaling of PR to moesin in T47-D cells: RhoA. (A) and (B) RhoA 
activity was assayed in cells treated with progesterone or MPA (both 100 nM) for 15 min in 
the presence or absence of the pure PR antagonist ORG 31710 (ORG - 1 µM), of the PI3K 
inhibitor wortmannin (WM - 30 nM), or of the G protein inhibitor, PTX (100 ng/mL). Active, 
GTP-bound RhoA was immunoprecipitated with Rhoteckin and subsequently assayed with 
western analysis with an anti-RhoA Ab (lower boxes). The upper boxes show the total RhoA 
content in the input. (C) and (D) T47-D cells were either mock-transfected or exposed to 
constitutively active or dominant-negative RhoA (RhoA CA or RhoA DN) and Gα13 (Gα13 
CA or Gα13 DN). Cells were then treated with progesterone or MPA (both 100 nM) for 15 
min and wild type and P-moesin were analyzed.  
 
Fig. 7. Extra-nuclear signaling of PR to moesin in T47-D cells: ROCK-2. (A) and (B) 
T47-D cells were exposed for 15 min to progesterone or MPA (both 100 nM) in the presence 
or absence of the ROCK-2 inhibitor, Y-27632 (Y - 10 µM) and moesin and phosphorylated 
moesin were assayed with western analysis. (C) T47-D cells were transfected with scrambled 
siRNA or ROCK-2 target siRNA for 48 h. ROCK-2 protein expression was detected by 
western blot. (D) Cells were exposed to 100 nM progesterone or MPA for 15 min after 
transfection with 100 nM target siRNA for ROCK-2 or scrambled siRNA for 48 h. Cell 
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contents of wild-type or phosphorylated moesin are shown. (E) and (F) Cells were treated 
with progesterone or MPA (both 100 nM) for 15 min in the presence or absence of ORG 
31710 (ORG - 1 µM), of wortmannin (WM - 30 nM), of PTX (100 ng/mL) or of Y-27632 (Y 
- 10 µM). ROCK-2 was immunoprecipitated with a specific Ab and the IPs were used to 
phosphorylate the bait protein, myelin basic protein (MBP). ROCK-2 kinase activity is shown 
as the amount of phosphorylated MBP (P-MBP). 
 
Fig. 8. PR activation increases T47-D cell migration. (A) and (B) Cells were treated with 
progesterone or MPA (both 100 nM) for 48 h, in the presence or absence of ORG 31710 
(ORG - 1 µM), of PD98059 (PD - 5 µM), of wortmannin (WM - 30 nM), of PTX (100 ng/mL) 
or of Y-27632 (Y - 10 µM). Other cells were transfected with moesin antisense 
phosphorotioate oligonucleotides (PON) (antisense - 2 µM) or sense PON (sense - 2 µM). 
T47-D cells were scraped out of the cell culture dish and the extent of migration of the 
remaining cells was assayed in the presence of Ara-C (see text). Cell migration distances 
were measured and values are presented as % of control. * = P<0.01 vs. control; ** = P<0.05 
vs. progesterone or MPA. The experiments were performed in triplicates and data 
representing the migration distance of cells from the starting line are expressed as mean ± SD. 
Representative images are shown. The arrows indicate the direction of migration. The upper 
black lines indicate the starting line and the lower black lines indicate the mean migration 
distance.  
 
Fig. 9. PR activation enhances T47-D cell invasion 
(A), (B) and (C) T47-D cells were treated with progesterone or MPA (both 100 nM) for 24 h, 
in the presence or absence of the same inhibitors as the previous or of transfection with 
moesin antisense phosphorotioate oligonucleotides (PON) (antisense - 2 µM) or sense PON 
(sense - 2 µM) for 48 h and cell invasion was assayed using invasion chambers. Invading 
cells were counted in three different central fields of triplicate membranes. Invasion indexes 
and representative images are shown. * = P<0.01 vs. control, ** = P<0.05 vs P or MPA. 
 
Fig. 10. PR activation induces changes in T47-D cells morphology and movement. T47-D 
cells were exposed to 100 nM P or MPA from 0 to 30 min. Cell morphology and cell 
movement was visualized and recorded by using time-lapse recording microscopy. 
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